Literature DB >> 33717266

SOX2 enhances cell survival and induces resistance to apoptosis under serum starvation conditions through the AKT/GSK-3β signaling pathway in esophageal squamous cell carcinoma.

Kei Terasaki1, Yasuyuki Gen1, Naoto Iwai1, Tomohiro Soda1, Tomoko Kitaichi1, Osamu Dohi1, Hiroyoshi Taketani1, Yuya Seko1, Atsushi Umemura1, Taichiro Nishikawa1, Kanji Yamaguchi1, Michihisa Moriguchi1, Hideyuki Konishi1, Yuji Naito1, Yoshito Itoh1, Kohichiroh Yasui2.   

Abstract

The human SOX2 gene was recently identified as a novel major oncogene, recurrently amplified and overexpressed in esophageal squamous cell carcinoma (ESCC). However, the role and molecular mechanism of SOX2 in the carcinogenesis of ESCC remain to be elucidated. The present study investigated the effect of SOX2 on ESCC cell survival and resistance to apoptosis under serum starvation conditions. An adenoviral vector-mediated expression system and RNA interference were used to study the effect of SOX2. The present results revealed that SOX2 promoted ESCC cell survival and enhanced resistance to apoptosis under serum starvation conditions, but not in culture conditions with serum. Mechanistically, SOX2 increased the expression levels of phosphorylated AKT and glycogen synthase kinase-3β (GSK-3β), a downstream factor of AKT, under serum starvation conditions, leading to the promotion of ESCC cell survival. Additionally, SOX2 activated AKT through the PTEN/PI3K/phosphoinositide-dependent protein kinase 1 and mammalian target of rapamycin complex 2 signaling pathways. Therefore, SOX2 may facilitate the survival of ESCC cells under poor nutrient conditions by activating the AKT/GSK-3β signaling pathway.
Copyright © 2021, Spandidos Publications.

Entities:  

Keywords:  AKT; SOX2; esophageal squamous cell carcinoma; serum starvation; survival

Year:  2021        PMID: 33717266      PMCID: PMC7885160          DOI: 10.3892/ol.2021.12530

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  20 in total

Review 1.  Sox genes find their feet.

Authors:  L H Pevny; R Lovell-Badge
Journal:  Curr Opin Genet Dev       Date:  1997-06       Impact factor: 5.578

Review 2.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

3.  Esophageal carcinoma.

Authors:  Anil K Rustgi; Hashem B El-Serag
Journal:  N Engl J Med       Date:  2014-12-25       Impact factor: 91.245

4.  SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway.

Authors:  Yasuyuki Gen; Kohichiroh Yasui; Taichiro Nishikawa; Toshikazu Yoshikawa
Journal:  Cancer Sci       Date:  2013-04-16       Impact factor: 6.716

5.  AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity.

Authors:  Christine M Chresta; Barry R Davies; Ian Hickson; Tom Harding; Sabina Cosulich; Susan E Critchlow; John P Vincent; Rebecca Ellston; Darren Jones; Patrizia Sini; Dominic James; Zoe Howard; Phillippa Dudley; Gareth Hughes; Lisa Smith; Sharon Maguire; Marc Hummersone; Karine Malagu; Keith Menear; Richard Jenkins; Matt Jacobsen; Graeme C M Smith; Sylvie Guichard; Martin Pass
Journal:  Cancer Res       Date:  2009-12-22       Impact factor: 12.701

6.  PRMT8 Controls the Pluripotency and Mesodermal Fate of Human Embryonic Stem Cells By Enhancing the PI3K/AKT/SOX2 Axis.

Authors:  Ho-Chang Jeong; Soon-Jung Park; Jong-Jin Choi; Young-Hyun Go; Soon-Ki Hong; Ok-Seon Kwon; Joong-Gon Shin; Rae-Kwon Kim; Mi-Ok Lee; Su-Jae Lee; Hyoung Doo Shin; Sung-Hwan Moon; Hyuk-Jin Cha
Journal:  Stem Cells       Date:  2017-05-31       Impact factor: 6.277

7.  A Positive Feedback Loop between Akt and mTORC2 via SIN1 Phosphorylation.

Authors:  Guang Yang; Danielle S Murashige; Sean J Humphrey; David E James
Journal:  Cell Rep       Date:  2015-07-30       Impact factor: 9.423

8.  SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas.

Authors:  Adam J Bass; Hideo Watanabe; Craig H Mermel; Soyoung Yu; Sven Perner; Roel G Verhaak; So Young Kim; Leslie Wardwell; Pablo Tamayo; Irit Gat-Viks; Alex H Ramos; Michele S Woo; Barbara A Weir; Gad Getz; Rameen Beroukhim; Michael O'Kelly; Amit Dutt; Orit Rozenblatt-Rosen; Piotr Dziunycz; Justin Komisarof; Lucian R Chirieac; Christopher J Lafargue; Veit Scheble; Theresia Wilbertz; Changqing Ma; Shilpa Rao; Hiroshi Nakagawa; Douglas B Stairs; Lin Lin; Thomas J Giordano; Patrick Wagner; John D Minna; Adi F Gazdar; Chang Qi Zhu; Marcia S Brose; Ivan Cecconello; Ulysses Ribeiro; Suely K Marie; Olav Dahl; Ramesh A Shivdasani; Ming-Sound Tsao; Mark A Rubin; Kwok K Wong; Aviv Regev; William C Hahn; David G Beer; Anil K Rustgi; Matthew Meyerson
Journal:  Nat Genet       Date:  2009-10-04       Impact factor: 38.330

9.  Molecular and functional interactions between AKT and SOX2 in breast carcinoma.

Authors:  Thorsten Schaefer; Hui Wang; Perihan Mir; Martina Konantz; Tamara C Pereboom; Anna M Paczulla; Britta Merz; Tanja Fehm; Sven Perner; Oliver C Rothfuss; Lothar Kanz; Klaus Schulze-Osthoff; Claudia Lengerke
Journal:  Oncotarget       Date:  2015-12-22

10.  Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods.

Authors:  J Ferlay; M Colombet; I Soerjomataram; C Mathers; D M Parkin; M Piñeros; A Znaor; F Bray
Journal:  Int J Cancer       Date:  2018-12-06       Impact factor: 7.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.